Schizophrenia Bulletin Advance Access originally published online on July 14, 2007
Schizophrenia Bulletin 2007 33(5):1131-1137; doi:10.1093/schbul/sbm081
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cognitive Neuroscience-Based Approaches to Measuring and Improving Treatment Effects on Cognition in Schizophrenia: The CNTRICS Initiative
2 University of California at Davis
3 Departments of Psychology, Psychiatry, and Radiology, Washington University, One Brookings Drive, St Louis, MO 63130
1 To whom correspondence should be addressed; tel: 314-935-8729, fax: 314-935-8790, e-mail: dbarch{at}artsci.wustl.edu.
The goal of this article is to discuss ways to further improve the search for potentially procognitive agents that could be used to enhance cognition and functional outcome in schizophrenia. In particular, we focus on the potential advantages to this process of using a contemporary, cognitive neuroscience-based approach to measuring cognitive function in clinical trials of procognitive agents in schizophrenia. These tools include computer-administered tasks that measure specific cognitive systems (such as attention, working memory, long-term memory, cognitive control) as well as the component cognitive processes that comprise these more overarching systems. The advantages of using these tools include the ability to identify and use homologous animal and human models in the drug discovery and testing process and the ability to incorporate noninvasive functional imaging measures into clinical trial contexts at several different phases of the drug development process. However, despite the clear potential advantages to using such methods, a number of barriers exist to their translation from basic science tools to tools for drug discovery. We discuss the development and implementation of a new project, Cognitive Neuroscience Treatment to Improve Cognition in Schizophrenia, designed to identify and overcome these barriers to the translation of cognitive neuroscience measures and methods into regular use in the drug discovery and development process of cognition-enhancing agents for use in schizophrenia.
Keywords: pharmacology / cognitive / imaging
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
J. H. Yoon, A. S. Rokem, M. A. Silver, M. J. Minzenberg, S. Ursu, J. D. Ragland, and C. S. Carter Diminished Orientation-Specific Surround Suppression of Visual Processing in Schizophrenia Schizophr Bull, November 1, 2009; 35(6): 1078 - 1084. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Ragland, A. R. Laird, C. Ranganath, R. S. Blumenfeld, S. M. Gonzales, and D. C. Glahn Prefrontal Activation Deficits During Episodic Memory in Schizophrenia Am J Psychiatry, August 1, 2009; 166(8): 863 - 874. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Dickinson and P. D. Harvey Systemic Hypotheses for Generalized Cognitive Deficits in Schizophrenia: A New Take on An Old Problem Schizophr Bull, March 1, 2009; 35(2): 403 - 414. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Ragland, R. Cools, M. Frank, D. A. Pizzagalli, A. Preston, C. Ranganath, and A. D. Wagner CNTRICS Final Task Selection: Long-Term Memory Schizophr Bull, January 1, 2009; 35(1): 197 - 212. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Barch, T. S. Braver, C. S. Carter, R. A. Poldrack, and T. W. Robbins CNTRICS Final Task Selection: Executive Control Schizophr Bull, January 1, 2009; 35(1): 115 - 135. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Barch, C. S. Carter, A. Arnsten, R. W. Buchanan, J. D. Cohen, M. Geyer, M. F. Green, J. H. Krystal, K. Nuechterlein, T. Robbins, et al. Selecting Paradigms From Cognitive Neuroscience for Translation into Use in Clinical Trials: Proceedings of the Third CNTRICS Meeting Schizophr Bull, January 1, 2009; 35(1): 109 - 114. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Dickinson Digit symbol coding and general cognitive ability in schizophrenia: worth another look? The British Journal of Psychiatry, November 1, 2008; 193(5): 354 - 356. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Silverstein Measuring Specific, Rather than Generalized, Cognitive Deficits and Maximizing Between-Group Effect Size in Studies of Cognition and Cognitive Change Schizophr Bull, July 1, 2008; 34(4): 645 - 655. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. F. Green and D. I. Leitman Social Cognition in Schizophrenia Schizophr Bull, July 1, 2008; 34(4): 670 - 672. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Marder Neurocognition as a Treatment Target in Schizophrenia Focus, April 1, 2008; 6(2): 180 - 183. [Abstract] [Full Text] [PDF] |
||||



